Revolution Medicines officer sells 3,121 shares

The Chief Global Commercialization Officer's options vest 25% on the first anniversary of April 1, 2025, then 1/48 monthly, subject to continued service.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) Chief Global Commercialization Officer Anthony Mancini exercised options for 3,121 common shares on September 25, 2026, at an exercise price of $33.62 per share, then sold 3,121 shares at $200.54 per share. He also sold 587 shares at $200 per share on September 24, 2026. All reported transactions were made under a Rule 10b5-1 trading plan adopted June 11, 2026. The reported option position after the exercise was 93,625 shares.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Mancini Anthony

Role See Remarks

Sold 3,708 shs ($743K)

Approx. gross sale proceeds $743K

Approx. exercise cost $105K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	3,121	$0.00	$0.00
Exercise	Common Stock F1	3,121	$33.62	$105K
Sale	Common Stock F1, F2	3,121	$200.54	$626K
Sale	Common Stock F1	587	$200.00	$117K

Holdings After Transaction: Stock Option (Right to Buy) — 93,625 contracts (Direct); Common Stock — 39,765 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
2. F2. Includes 39,575 restricted stock units.
3. F3. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Options exercised: 3,121 shares Exercise price: $33.62 per share Shares sold: 3,121 shares +5 more

8 metrics

Options exercised 3,121 shares September 25, 2026

Exercise price $33.62 per share Options exercised September 25, 2026

Shares sold 3,121 shares September 25, 2026

Sale price $200.54 per share Sale on September 25, 2026

Shares sold 587 shares September 24, 2026

Sale price $200 per share Sale on September 24, 2026

Option shares following exercise 93,625 shares Reported following the September 25, 2026 transaction

Rule 10b5-1 trading plan adoption June 11, 2026 Plan covering the reported transactions

Key Terms

Stock Option (Right to Buy), Rule 10b5-1 trading plan, restricted stock units, Vesting Commencement Date

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Rule 10b5-1 trading plan financial

"Transaction made pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 39,575 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date financial

"the "Vesting Commencement Date""

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What trades did RVMD's Chief Global Commercialization Officer report?

Anthony Mancini exercised options for 3,121 shares at $33.62 per share on September 25, 2026, and sold 3,121 shares at $200.54 per share that day. He also sold 587 shares at $200 per share on September 24, 2026. The transactions were made under a Rule 10b5-1 trading plan adopted June 11, 2026.

How do Anthony Mancini's RVMD options vest?

Twenty-five percent of the shares subject to the option vest on the first-year anniversary measured from April 1, 2025. One forty-eighth of the shares subject to the option vests on each monthly anniversary thereafter, with all shares fully vested and exercisable as of the fourth anniversary, subject to continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 06:00 PM Accepted by SEC EDGAR 09/28/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2026		S(1)		587	D	$200	39,765	D
Common Stock	09/25/2026		M(1)		3,121	A	$33.62	42,886	D
Common Stock	09/25/2026		S(1)		3,121	D	$200.54	39,765(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.62	09/25/2026		M(1)			3,121	(3)	03/31/2035	Common Stock	3,121	$0	93,625	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

2. Includes 39,575 restricted stock units.

3. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)